Ellis Andrea

Director Ellis Andrea sold 64.9K BBIO shares ($4.2M) at $64.87; post-sale holdings fell to 18.6K (-77.7%). Stock down 18.2% from 52-week high.

Ellis Andrea, a Director, sold 64,921 shares for $4,211,301.92 at $64.87, reducing her stake from 83,510 to 18,589 shares—a 77.7% reduction in holdings. The sale occurred as the stock trades -18.2% from its 52-week high of $79.91 and has declined 13.1% over the prior 30 days. Her prior sell at BBIO on 2025-04-01 achieved a 90-day return of +26.8%, indicating the stock subsequently rose after that sale—poorly timed from an exit-timing perspective. The company remains unprofitable (net income of $-184.9M on revenue of $120.7M) despite strong revenue growth of +126.3% year-over-year. This substantial liquidation of director-level holdings warrants monitoring, particularly given the company's pre-profitability stage and recent price weakness.

Director Ellis Andrea sold 30,000 shares of BBIO at $34.05 on 2025-04-01; reduced position by 71.4% to 12,000 shares

Ellis Andrea, a director of BridgeBio Pharma, executed a substantial share reduction on 2025-04-01, selling 30,000 shares at $34.05, reducing her holdings from 42,000 shares to 12,000 shares—a 71.4% reduction in her position. This divestiture is notable given the company's financial profile: despite a 52-week share price range of $22.35–$37.59, BridgeBio reported a net income of $-164,254,000.00 in its most recent full fiscal year and continues to generate massive losses while revenue sits at $2,732,000.00 for the latest quarter. The substantial nature of the position reduction—removing over two-thirds of her prior holdings—warrants attention to the company's near-term outlook, particularly given the company's deep unprofitability and the director's shift from material shareholder to a minimal 12,000-share stake.